

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Albania	Guyana	Pakistan
Argentina	Haiti	Panama
Armenia	Honduras	Peru
Aruba	Hong Kong	Qatar
Australia	Israel	Republic of Korea
Azerbaijan	Jamaica	Saudi Arabia
Bahrain	Japan	Serbia
Bosnia and Herzegovina	Jordan	Singapore
Botswana	Kazakhstan	South Africa
Brazil	Kenya	Switzerland
Canada	Kuwait	Taiwan
Chile	Kyrgyzstan	Thailand
China	Lebanon	Trinidad and Tobago
Colombia	Macau	Turkey
Costa Rica	Macedonia	Uganda
Curacao	Mexico	Ukraine
Dominican Republic	Moldova	United Arab Emirates
Ecuador	Mongolia	United Kingdom
El Salvador	Morocco	United States of America
European Union	Namibia	Uruguay
Georgia	New Zealand	Uzbekistan
Ghana	Nigeria	
Guatemala	Oman	

- ✓ **"Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.**
- ✓ **Granted Marketing Authorisations may include limitations on the use of the product.**

This document was prepared on 18 Mar 2022 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.